Main description:

This highly informative and clearly written book presents the basic science and the latest data on hereditary breast and ovarian cancer (HBOC) to provide an up-to-date and holistic overview of the disease. It starts off by presenting the molecular mechanisms, genetic testing and counseling, and variants of unknown significance (VUS) to help readers understand the contemporary interpretation of the disease. Further chapters focus on the surveillance, diagnosis and treatment, including chemoprevention, risk reduction and drug development based on molecular mechanisms. It also includes a chapter on the latest findings from the HBOC database, ethical issues and the parp inhibitors, and discusses innovative thinking to manage and understand the disease.
Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice offers breast surgeons, medical oncologists, gynecological oncologists and genetic counselors a comprehensive overview of the disease. Providing insights into recent scientific findings and further avenues for investigation, it is also a thought-provoking and informative read for researchers and scholars.

Contents:

1 History, Advancements, and Future Strategies 2 Molecular basis of BRCA1 and BRCA2 - Homologous recombination deficiency and tissue-specific carcinogenesis 3 Genetic Testing 4 Variants of uncertain significances in hereditary breast and ovarian cancer 5 Genetic counseling in Hereditary Breast and Ovarian Cancer 6 Hereditary Breast Cancer 7 Hereditary Ovarian Cancer 8 Risk-Based Breast Cancer Screening 9 Chemoprevention for Breast Cancer 10 Chemoprevention for Ovarian Cancer 11 Risk-Reducing Mastectomy (RRM) 12 Risk-reducing salpingo-oophorectomy (RRSO) 13 Panel Testing 14 Germline Findings through Precision Oncology for Ovarian Cancer
15 Germline Findings from Genetic Testing for Breast Cancer 16 Hereditary Breast and Ovarian Cancer (HBOC) Database 17 Ethical Issues: Overview in Genomic analysis and Clinical Context
18 PARP Inhibitors-Mechanism of action 19 PARPi - Efficacy in Hereditary Breast Cancer 20 Efficacy of Poly ADP-Ribose Polymerase Inhibitors for Hereditary Ovarian Cancer